Zhitong Finance App News, Shanghai Laishi (002252.SZ) announced that Guangxi Laishi Biopharmaceutical Co., Ltd. (“Guangxi Laishi”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” from the China Drug Administration (hereinafter referred to as the “State Drug Administration”) on November 5, 2026, regarding the registration and marketing license application for the “human blood albumin” drug.

According to reports, human albumin is mainly used for hemorrhagic trauma, shock caused by burns; cerebral edema and increased intracranial pressure due to injury; oedema or ascites caused by cirrhosis and kidney disease; prevention and treatment of hypoproteinemia; neonatal hyperbilirubinemia; for cardiopulmonary shunt surgery, adjuvant treatment of burns, adjuvant treatment of hemodialysis, and adult respiratory distress syndrome.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.